Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.39 |
| ▸ | NPY1R | P25929 | 7/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390888 | 0.96 | NPY5R (0.40) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30898574 | 0.94 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29658786 | 0.94 | FURIN (0.38) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30123286 | 0.94 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL9819642 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29697049 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL9819648 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29540259 | 0.92 | NOD1 (0.46) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29740225 | 0.92 | NOD1 (0.46) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30685283 | 0.91 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | NPY4R 58/4885NPY1R 121/4885NPY2R 141/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | NPY4R 58/4885NPY1R 121/4885NPY2R 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.